Management of H. pylori and Short-Segment Barrett's Esophagus Without Dysplasia
This 57-year-old female requires H. pylori eradication therapy followed by confirmation of eradication, and endoscopic surveillance of her short-segment Barrett's esophagus every 3-5 years.
H. pylori Management
Eradication Treatment
The H. pylori infection found on antral biopsies must be treated. Use bismuth-containing quadruple therapy as first-line treatment if available, or sequential therapy as an alternative 1. The choice depends on local clarithromycin resistance patterns—in high-resistance areas, bismuth quadruple therapy is mandatory.
Confirmation of Eradication
Testing for successful eradication must occur at least 4 weeks after completing treatment 1. Use either:
- Urea breath test (UBT), or
- Laboratory-based validated monoclonal stool antigen test
Do not use serology for post-treatment confirmation 1.
Important Consideration Regarding H. pylori and Barrett's
While recent research suggests H. pylori infection may be associated with lower progression risk from nondysplastic Barrett's to dysplasia 2, and that eradication therapy may attenuate this protective effect 2, this should not alter the decision to treat H. pylori. The established benefits of H. pylori eradication for peptic ulcer disease and gastric cancer prevention take precedence over theoretical concerns about Barrett's progression.
Barrett's Esophagus Surveillance
Current Status Confirmation
Since this is short-segment Barrett's without dysplasia, ensure:
- The Barrett's segment length is documented using Prague classification 3, 4
- Intestinal metaplasia is confirmed on histology 5
- High-definition white-light endoscopy was used 3, 4
- Seattle protocol biopsies (4-quadrant biopsies every 1-2 cm) were obtained 3, 5
Surveillance Interval
For short-segment Barrett's esophagus (<3 cm) with intestinal metaplasia and no dysplasia, perform surveillance endoscopy every 3-5 years 5, 6. The most recent AGA guidance (2022) supports surveillance intervals of 3-5 years for nondysplastic Barrett's 3.
Acid Suppression
Place the patient on at least daily proton pump inhibitor (PPI) therapy 3. This is recommended for all Barrett's patients regardless of symptoms.
Surveillance Protocol Requirements
At each surveillance endoscopy:
- Use high-definition white-light endoscopy with virtual chromoendoscopy 3, 4
- Spend adequate inspection time (≥1 minute per cm of Barrett's segment) 4
- Obtain 4-quadrant biopsies every 1-2 cm using Seattle protocol 3, 5
- Target any visible lesions separately before random biopsies 7
- Avoid biopsies during active severe esophagitis (Los Angeles grade C or D); optimize PPI therapy for 8 weeks first, then repeat endoscopy 7, 4
Common Pitfalls to Avoid
Do not perform surveillance more frequently than recommended (every 3-5 years for nondysplastic Barrett's). Over-surveillance increases costs and procedural risks without proven benefit 6.
Do not discharge from surveillance even if H. pylori is eradicated. The Barrett's esophagus requires ongoing monitoring regardless of H. pylori status.
Ensure expert pathology review if any dysplasia is suspected on future surveillance, as interobserver variability among pathologists is significant 5, 7, 5.
Document intestinal metaplasia on cardia biopsies separately—intestinal metaplasia at the cardia alone does not warrant Barrett's surveillance 5.
If Dysplasia Develops on Future Surveillance
Should low-grade dysplasia be detected:
- Confirm with expert GI pathologist 7
- Repeat endoscopy in 8-12 weeks on twice-daily PPI 7
- If confirmed and persistent, discuss endoscopic eradication therapy vs. surveillance every 6 months 7
Should high-grade dysplasia be detected: